Saredutant

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Saredutant
Saredutant.svg
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
ChEMBL
ECHA InfoCard 100.111.408
Chemical and physical data
Formula C31H35Cl2N3O2
Molar mass 552.5345 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Saredutant (SR-48,968) is a drug that acts as a NK2 receptor antagonist. It was under development by Sanofi-Aventis as a novel antidepressant and anxiolytic and made it to phase III clinical trials. However, in May 2009, Sanofi-Aventis published its quarterly results and announced the cessation of 14 research/development projects, among which was saredutant for the treatment of major depressive disorder.[1]

See also[edit]

References[edit]

  1. ^ http://www.sanofi-aventis.com/binaries/Lettre18_FR_Web_acc_tcm29-25341.pdf Letter to the stockholders of Sanofi-Aventis on May 2009